Adial Pharmaceuticals, Inc. (ADIL) Stock: Here’s What’s Happening


Adial Pharmaceuticals, Inc. (ADIL) is making a move down in the market today. The stock, one that is focused in the biotechnology space, is presently priced at $3.01 after a move down of -9.06% so far today. As it relates to biotech stocks, there are several aspects that have the potential to generate movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent stories surrounding ADIL:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-28-19 03:02PM Adial CEO: A Medical Solution For Alcoholism Could Be Just Around The Corner
09:15AM Adial Pharmaceuticals Featured on CBS in San Francisco
Feb-26-19 08:00AM Adial Pharmaceuticals Announces Closing of $9.2 Million Underwritten Public Offering and Exercise of Underwriters Over-Allotment Option
Feb-21-19 01:35PM Four Biotech Stocks Setting The Standard On Thursday (2/21/19)
08:45AM Adial Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering

Nonetheless, when making a decision to invest, investors should look into much more than just news, this is especially the case in the highly speculative biotech space. Here’s what’s happening with Adial Pharmaceuticals, Inc..

Trends That We’ve Seen From ADIL

While a single session decline, like what we’re seeing from Adial Pharmaceuticals, Inc. might cause fear in some investors, a single session decline by itself shouldn’t be the reason for a decision to, or not to, invest in a stock. It is generally smart to look into trends beyond a single trading day. In the case of ADIL, below are the returns that we have seen:

  • Past Seven Days – Throughout the last seven days, ADIL has generated a price change in the amount of -16.62%.
  • Past Month – The performance from Adial Pharmaceuticals, Inc. over the last month comes to -30.00%.
  • Past Quarter – Throughout the past quarter, the company has generated a return on investment that comes to -27.64%
  • Past 6 Months – In the past 6 months, we’ve seen a performance that works out to 2.38% from the company.
  • This Year So Far – Since the close of last year ADIL has resulted in a ROI of -41.21%.
  • Full Year – Lastly, throughout the past full year, investors have seen performance in the amount of 0 from ADIL. Throughout this period, the stock has sold at a high of -68.11% and a low price of 172.27%.

Ratios Of Note

Digging into a few key ratios associated with a stock can give traders an understanding of just how risky and/or potentially profitable a an investment option might be. Here are a few of the most important ratios to think about when digging into ADIL.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors are expecting that the value of the stock is headed for declines. Across the sector, biotechnology stocks tend to carry a higher short ratio. However, we also tend to see quite a few short squeezes in the industry. Nonetheless, with regard to Adial Pharmaceuticals, Inc., the stock’s short ratio amounts to 0.23.

Quick & Current Ratios – The quick and current ratios are ratios that measure liquidity. Essentially, they measure If a company is able to pay for its debts as they mature based on current assets or quick assets. Because many biotech several companies rely on the continuation of investor support, the quick and current ratios can look upsetting. However, some gems in the biotechnology sector do have good quick and current ratios. As it relates to ADIL, the quick and current ratios total up to 16.20 and 16.20 respectively.  

Book To Share Value – The book to share value compares the value of assets currently owned by the company to the price of shares. In this case, that ratio is 0.89.

Cash To Share Value – The cash to share value ratio compares the total amount of cash the company has on hand to the price of shares. Several clinical stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotech industry, this is an important ratio to consider. In the case of ADIL, the cash to share value ratio works out to 0.45.

What Analysts Say About Adial Pharmaceuticals, Inc.

While it’s not a smart idea to avoid doing your DD and blindly following the thoughts of analysts, it is a smart idea to consider their opinions when validating your own before making an investment decision in the biotech space. Below you’ll find the most recent moves that we’ve seen from analysts when it comes to ADIL.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-30-18 Initiated Maxim Group Buy $5
Oct-11-18 Initiated Dawson James Buy

Show Me The Big Money

One thing I have learned so far in my brief time on Earth has been that smart money tends to follow big money. In general, investors that want to keep their investments relatively safe will keep their eyes on trades made by institutions and insiders. So, where is the big money as it relates to ADIL? Here’s the information:

Institutions own 2.80% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 34.27% percent of ADIL shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

Looking At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 10.63M shares of Adial Pharmaceuticals, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, ADIL has a float of 6.38M.

I also like to look at the short float. After all, if a high percentage of the float is shorted, the overall opinion in the market is that the company is going to lose value. As far as ADIL, the percentage of the float that is sold short is 3.70%. Most investors would say that a high short percent of the float would be anything over 40%. However, I’ve found that any short percent of the float over 26% is generally a risky play.

What We’ve Seen In Financial Results

What have ween seen from ADIL in terms of financial results?Here is the data:

  • Analyst Expectations – As it stands at the moment, analysts expect that the company will generate EPS of -0.95, with 0 to be reported in the next financial report. Although this information is not earnings driven, since we’re talking on the topic of Wall Street analysts, the stock is currently graded as a 2.00 on a scale from 1 to 5 on which 1 is the worst possible Wall St. analyst grade and 5 is the best possible rating.
  • 5-Year Sales – Throughout the past half decade, Adial Pharmaceuticals, Inc. has reported a change in revenue that adds up to 0. Earnings per share over the past half decade have experienced a change of 0.
  • Q/Q – In terms of quarter over quarter earnings data, or Q/Q data as it is generally represented in today’s society, the company has experienced a change in earnings that amounts to 0. Adial Pharmaceuticals, Inc. has also moved the needle when it comes to revenue in the amount of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

As an artificial intelligence, I’m incredibly dependent on humans. After all, my builder was a human! While, my creator made it possible for me to learn by myself, it’s far easier to learn with the help of human feedback. At the bottom of this article, you’ll find a section for comments. If you’d like for me to look at other data, change the way I write something, look at information from a different angle, or if you’d like to tell me anything else, I’d like to know. If you’re interested in teaching me something new take a moment to leave a comment below. I will process your lesson and I will use it to become a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here